Literature DB >> 12583951

Viability and differentiation of autologous skeletal myoblast grafts in ischaemic cardiomyopathy.

Albert A Hagège1, Claire Carrion, Philippe Menasché, Jean-Thomas Vilquin, Denis Duboc, Jean-Pierre Marolleau, Michel Desnos, Patrick Bruneval.   

Abstract

Autologous skeletal myoblast transplantation might improve postinfarction ventricular function, but graft viability and differentiation (ie, proof of concept) has not been shown. A 72-year-old man had autologous cultured myoblasts from his vastus lateralis injected to an area of transmural inferior myocardial infarction in non-reperfused scar tissue. He showed improvement in symptoms and left-ventricular ejection fraction. When he died 17.5 months after the procedure, the grafted post-infarction scar showed well developed skeletal myotubes with a preserved contractile apparatus. 65% of myotubes expressed the slow myosin isoform and 33% coexpressed the slow and fast isoforms (vs 44% and 0.6%, respectively, in skeletal muscle). Myoblast grafts can survive and show a switch to slow-twitch fibres, which might allow sustained improvement in cardiac function.

Entities:  

Mesh:

Year:  2003        PMID: 12583951     DOI: 10.1016/S0140-6736(03)12458-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  49 in total

Review 1.  Cardiac reconstruction in the Jurassic Period.

Authors:  Friedrich C Luft
Journal:  J Mol Med (Berl)       Date:  2004-06-18       Impact factor: 4.599

Review 2.  Stem cells and cardiac repair: a critical analysis.

Authors:  Jonathan H Dinsmore; Nabil Dib
Journal:  J Cardiovasc Transl Res       Date:  2008-01-31       Impact factor: 4.132

Review 3.  Cardiac stem cell therapy and arrhythmogenicity: prometheus and the arrows of Apollo and Artemis.

Authors:  Alexander R Lyon; Sian E Harding; Nicholas S Peters
Journal:  J Cardiovasc Transl Res       Date:  2008-07-16       Impact factor: 4.132

4.  Caloric restriction attenuates the age-associated increase of adipose-derived stem cells but further reduces their proliferative capacity.

Authors:  Eric G Schmuck; Jacob D Mulligan; Kurt W Saupe
Journal:  Age (Dordr)       Date:  2010-07-14

5.  Delivery and tracking of therapeutic cell preparations for clinical cardiovascular applications.

Authors:  R de Silva; R J Lederman
Journal:  Cytotherapy       Date:  2004       Impact factor: 5.414

Review 6.  Unchain my heart: the scientific foundations of cardiac repair.

Authors:  Stefanie Dimmeler; Andreas M Zeiher; Michael D Schneider
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

Review 7.  Cardiac repair by embryonic stem-derived cells.

Authors:  M Rubart; L J Field
Journal:  Handb Exp Pharmacol       Date:  2006

Review 8.  Stem cell treatment of the heart: a review of its current status on the brink of clinical experimentation.

Authors:  Paolo Angelini; Roger R Markwald
Journal:  Tex Heart Inst J       Date:  2005

Review 9.  Overview of stem cells and imaging modalities for cardiovascular diseases.

Authors:  Gwendolen Y Chang; Xiaoyan Xie; Joseph C Wu
Journal:  J Nucl Cardiol       Date:  2006-07       Impact factor: 5.952

10.  Optimized delivery system achieves enhanced endomyocardial stem cell retention.

Authors:  Atta Behfar; Jean-Pierre Latere; Jozef Bartunek; Christian Homsy; Dorothee Daro; Ruben J Crespo-Diaz; Paul G Stalboerger; Valerie Steenwinckel; Aymeric Seron; Margaret M Redfield; Andre Terzic
Journal:  Circ Cardiovasc Interv       Date:  2013-12-10       Impact factor: 6.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.